{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T04:18:47Z","timestamp":1794543527817,"version":"4.9.1"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2019,6,17]],"date-time":"2019-06-17T00:00:00Z","timestamp":1560729600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,6,17]],"date-time":"2019-06-17T00:00:00Z","timestamp":1560729600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Follicular lymphoma (FL) is a heterogeneous disease whose pathogenesis remains partially unknown. Around 20% of FL patients experience early progression or treatment-refractory disease and 2\u20133% of patients per year experience histological transformation (HT) into a more aggressive lymphoma (tFL). Here, we evaluate the immunoglobulin heavy chain variable (<jats:italic>IGHV<\/jats:italic>) gene usage and mutational status in 187 FL cases to assess its impact on clinical outcome and histological transformation. The <jats:italic>IGHV<\/jats:italic> gene repertoire was remarkably biased in FL. The <jats:italic>IGHV4-34<\/jats:italic> (14%), <jats:italic>IGHV3-23<\/jats:italic> (14%), <jats:italic>IGHV3-48<\/jats:italic> (10%), <jats:italic>IGHV3-30<\/jats:italic> (9%) and <jats:italic>IGHV3-21<\/jats:italic> (7%) genes accounted for more than half of the whole cohort. <jats:italic>IGHV3-48<\/jats:italic> was overrepresented in cases of tFL (19%) compared with non-transformed FL at 5 years (5%, <jats:italic>P<\/jats:italic>\u2009=\u20090.05). Patients with the <jats:italic>IGHV3-48<\/jats:italic> gene were significantly more likely to have had HT after 10 years than those who used other genes (71% vs. 25%, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.05), irrespective of the therapy they received. Moreover, <jats:italic>IGHV3-30<\/jats:italic> was also overrepresented in cases of FL (9%) and tFL (13%) compared with diffuse large B-cell lymphoma in which it was nearly absent. In conclusion, our results indicate a role for antigen selection in the development of FL, while the use of <jats:italic>IGHV3-48<\/jats:italic> could help predict histological transformation.<\/jats:p>","DOI":"10.1038\/s41408-019-0213-9","type":"journal-article","created":{"date-parts":[[2019,6,17]],"date-time":"2019-06-17T15:03:19Z","timestamp":1560783799000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Immunoglobulin gene rearrangement IGHV3-48 is a predictive marker of histological transformation into aggressive lymphoma in follicular lymphomas"],"prefix":"10.1038","volume":"9","author":[{"given":"Mar\u00eda","family":"Garc\u00eda-\u00c1lvarez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Alonso-\u00c1lvarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Prieto-Conde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Jim\u00e9nez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Eugenia","family":"Sarasquete","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Carmen","family":"Chill\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Medina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Balanzategui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebeca","family":"Maldonado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Ant\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noem\u00ed","family":"Puig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oscar","family":"Blanco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Tamayo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ver\u00f3nica","family":"Gonz\u00e1lez-Calle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4120-2787","authenticated-orcid":false,"given":"Ram\u00f3n","family":"Garc\u00eda-Sanz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcos","family":"Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Dolores","family":"Caballero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3819-4846","authenticated-orcid":false,"given":"Miguel","family":"Alcoceba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,6,17]]},"reference":[{"key":"213_CR1","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.beha.2017.10.006","volume":"31","author":"T Lackraj","year":"2018","unstructured":"Lackraj, T., Goswami, R. & Kridel, R. Pathogenesis of follicular lymphoma. Best Pract. Res. Clin. Haematol. 31, 2\u201314 (2018).","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"213_CR2","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/S0140-6736(10)62175-7","volume":"377","author":"G Salles","year":"2011","unstructured":"Salles, G. et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet 377, 42\u201351 (2011).","journal-title":"Lancet"},{"key":"213_CR3","unstructured":"Swerdlow, S. H. et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues 4th edn, (IARC Press, 2017)."},{"key":"213_CR4","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1200\/JCO.2014.59.7534","volume":"33","author":"C Casulo","year":"2015","unstructured":"Casulo, C. et al. Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the national lymphocare study. J. Clin. Oncol. 33, 2516\u20132522 (2015).","journal-title":"J. Clin. Oncol."},{"key":"213_CR5","doi-asserted-by":"publisher","first-page":"2944","DOI":"10.1182\/blood-2013-11-531327","volume":"123","author":"IW Flinn","year":"2014","unstructured":"Flinn, I. W. et al. Randomized trial of bendamustine-rituximab or R-CHOP\/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood 123, 2944\u20132952 (2014).","journal-title":"Blood"},{"key":"213_CR6","doi-asserted-by":"crossref","unstructured":"Alcoceba M., Alonso-Alvarez S., Garc\u00eda-\u00c1lvarez M., Mart\u00edn A. & Caballero M. D. Unmet needs in histological transformation of follicular lymphoma: a clinical and biological review. Ann. Lymphoma 1, 11 2017.","DOI":"10.21037\/aol.2017.11.03"},{"key":"213_CR7","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s00277-017-3151-2","volume":"97","author":"T Fischer","year":"2018","unstructured":"Fischer, T., Zing, N. P. C., Chiattone, C. S., Federico, M. & Luminari, S. Transformed follicular lymphoma. Ann. Hematol. 97, 17\u201329 (2018).","journal-title":"Ann. Hematol."},{"key":"213_CR8","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1182\/blood-2014-04-516815","volume":"125","author":"C Casulo","year":"2015","unstructured":"Casulo, C., Burack, W. R. & Friedberg, J. W. Transformed follicular non-Hodgkin lymphoma. Blood 125, 40\u201347 (2015).","journal-title":"Blood"},{"key":"213_CR9","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1111\/bjh.14831","volume":"178","author":"S Alonso-Alvarez","year":"2017","unstructured":"Alonso-Alvarez, S. et al. Risk of, and survival following, histological transformation in follicular lymphoma in the rituximab era. A retrospective multicentre study by the Spanish GELTAMO group. Br. J. Haematol. 178, 699\u2013708 (2017).","journal-title":"Br. J. Haematol."},{"key":"213_CR10","doi-asserted-by":"publisher","first-page":"2426","DOI":"10.1200\/JCO.2006.09.3260","volume":"25","author":"S Montoto","year":"2007","unstructured":"Montoto, S. et al. Risk and clinical implications of transformation of follicular lymphoma to diffuse large B-cell lymphoma. J. Clin. Oncol. 25, 2426\u20132433 (2007).","journal-title":"J. Clin. Oncol."},{"key":"213_CR11","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","volume":"104","author":"P Solal-Celigny","year":"2004","unstructured":"Solal-Celigny, P. et al. Follicular lymphoma international prognostic index. Blood 104, 1258\u20131265 (2004).","journal-title":"Blood"},{"key":"213_CR12","doi-asserted-by":"publisher","first-page":"4555","DOI":"10.1200\/JCO.2008.21.3991","volume":"27","author":"M Federico","year":"2009","unstructured":"Federico, M. et al. Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J. Clin. Oncol. 27, 4555\u20134562 (2009).","journal-title":"J. Clin. Oncol."},{"key":"213_CR13","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1182\/blood-2017-03-691345","volume":"130","author":"R Kridel","year":"2017","unstructured":"Kridel, R., Sehn, L. H. & Gascoyne, R. D. Can histologic transformation of follicular lymphoma be predicted and prevented? Blood 130, 258\u2013266 (2017).","journal-title":"Blood"},{"key":"213_CR14","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/j.leukres.2015.03.003","volume":"39","author":"E Berget","year":"2015","unstructured":"Berget, E., Molven, A., Lokeland, T., Helgeland, L. & Vintermyr, O. K. IGHV gene usage and mutational status in follicular lymphoma: correlations with prognosis and patient age. Leuk. Res. 39, 702\u2013708 (2015).","journal-title":"Leuk. Res."},{"key":"213_CR15","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1182\/blood.V94.6.1840","volume":"94","author":"RN Damle","year":"1999","unstructured":"Damle, R. N. et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 94, 1840\u20131847 (1999).","journal-title":"Blood"},{"key":"213_CR16","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1182\/blood.V94.6.1848","volume":"94","author":"TJ Hamblin","year":"1999","unstructured":"Hamblin, T. J., Davis, Z., Gardiner, A., Oscier, D. G. & Stevenson, F. K. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 94, 1848\u20131854 (1999).","journal-title":"Blood"},{"key":"213_CR17","doi-asserted-by":"publisher","first-page":"2262","DOI":"10.1182\/blood.V99.6.2262","volume":"99","author":"G Tobin","year":"2002","unstructured":"Tobin, G. et al. Somatically mutated Ig V(H)3-21 genes characterize a new subset of chronic lymphocytic leukemia. Blood 99, 2262\u20132264 (2002).","journal-title":"Blood"},{"key":"213_CR18","doi-asserted-by":"publisher","first-page":"4042","DOI":"10.1182\/blood-2002-11-3456","volume":"101","author":"FI Camacho","year":"2003","unstructured":"Camacho, F. I. et al. Molecular heterogeneity in MCL defined by the use of specific VH genes and the frequency of somatic mutations. Blood 101, 4042\u20134046 (2003).","journal-title":"Blood"},{"key":"213_CR19","doi-asserted-by":"publisher","first-page":"635","DOI":"10.3324\/haematol.10755","volume":"92","author":"P Martin-Jimenez","year":"2007","unstructured":"Martin-Jimenez, P. et al. Molecular characterization of heavy chain immunoglobulin gene rearrangements in Waldenstrom\u2019s macroglobulinemia and IgM monoclonal gammopathy of undetermined significance. Haematologica 92, 635\u2013642 (2007).","journal-title":"Haematologica"},{"key":"213_CR20","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1093\/intimm\/dxq441","volume":"22","author":"NS Zuckerman","year":"2010","unstructured":"Zuckerman, N. S. et al. Ig gene diversification and selection in follicular lymphoma, diffuse large B cell lymphoma and primary central nervous system lymphoma revealed by lineage tree and mutation analyses. Int. Immunol. 22, 875\u2013887 (2010).","journal-title":"Int. Immunol."},{"key":"213_CR21","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1016\/j.ajpath.2012.07.028","volume":"181","author":"E Sebastian","year":"2012","unstructured":"Sebastian, E. et al. Molecular characterization of immunoglobulin gene rearrangements in diffuse large B-cell lymphoma: antigen-driven origin and IGHV4-34 as a particular subgroup of the non-GCB subtype. Am. J. Pathol. 181, 1879\u20131888 (2012).","journal-title":"Am. J. Pathol."},{"key":"213_CR22","doi-asserted-by":"publisher","first-page":"e197","DOI":"10.3324\/haematol.2014.107680","volume":"99","author":"G Brisou","year":"2014","unstructured":"Brisou, G. et al. A restricted IGHV gene repertoire in splenic marginal zone lymphoma is associated with autoimmune disorders. Haematologica 99, e197\u2013e198 (2014).","journal-title":"Haematologica"},{"key":"213_CR23","doi-asserted-by":"publisher","first-page":"5101","DOI":"10.1182\/blood-2007-12-130229","volume":"111","author":"EM Ghia","year":"2008","unstructured":"Ghia, E. M. et al. Use of IGHV3-21 in chronic lymphocytic leukemia is associated with high-risk disease and reflects antigen-driven, post-germinal center leukemogenic selection. Blood 111, 5101\u20135108 (2008).","journal-title":"Blood"},{"key":"213_CR24","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1182\/blood-2014-09-600874","volume":"125","author":"P Baliakas","year":"2015","unstructured":"Baliakas, P. et al. Not all IGHV3-21 chronic lymphocytic leukemias are equal: prognostic considerations. Blood 125, 856\u2013859 (2015).","journal-title":"Blood"},{"key":"213_CR25","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1182\/blood.V78.6.1561.1561","volume":"78","author":"DW Bahler","year":"1991","unstructured":"Bahler, D. W. et al. gene expression among human follicular lymphomas. Blood 78, 1561\u20131568 (1991).","journal-title":"Blood"},{"key":"213_CR26","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1046\/j.1365-2141.1999.01732.x","volume":"107","author":"SM Noppe","year":"1999","unstructured":"Noppe, S. M. et al. The genetic variability of the VH genes in follicular lymphoma: the impact of the hypermutation mechanism. Br. J. Haematol. 107, 625\u2013640 (1999).","journal-title":"Br. J. Haematol."},{"key":"213_CR27","doi-asserted-by":"crossref","first-page":"2922","DOI":"10.1182\/blood.V95.9.2922.009k38_2922_2929","volume":"95","author":"WM Aarts","year":"2000","unstructured":"Aarts, W. M. et al. Variable heavy chain gene analysis of follicular lymphomas: correlation between heavy chain isotype expression and somatic mutation load. Blood 95, 2922\u20132929 (2000).","journal-title":"Blood"},{"key":"213_CR28","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s11864-017-0483-z","volume":"18","author":"RC Lynch","year":"2017","unstructured":"Lynch, R. C., Gratzinger, D. & Advani, R. H. Clinical Impact of the 2016 update to the WHO lymphoma classification. Curr. Treat. Options Oncol. 18, 45 (2017).","journal-title":"Curr. Treat. Options Oncol."},{"key":"213_CR29","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.exppara.2017.04.010","volume":"177","author":"AE Casaril","year":"2017","unstructured":"Casaril, A. E. et al. Standardization of DNA extraction from sand flies: application to genotyping by next generation sequencing. Exp. Parasitol. 177, 66\u201372 (2017).","journal-title":"Exp. Parasitol."},{"key":"213_CR30","first-page":"779","volume":"84","author":"M Gonzalez","year":"1999","unstructured":"Gonzalez, M. et al. Heteroduplex analysis of VDJ amplified segments from rearranged IgH genes for clonality assessments in B-cell non-Hodgkin\u2019s lymphoma. A comparison between different strategies. Haematologica 84, 779\u2013784 (1999).","journal-title":"Haematologica"},{"key":"213_CR31","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.1038\/sj.leu.2403202","volume":"17","author":"JJ Van Dongen","year":"2003","unstructured":"Van Dongen, J. J. et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia 17, 2257\u20132317 (2003).","journal-title":"Leukemia"},{"key":"213_CR32","doi-asserted-by":"crossref","first-page":"3275","DOI":"10.1182\/blood.V78.12.3275.3275","volume":"78","author":"JG Gribben","year":"1991","unstructured":"Gribben, J. G. et al. All advanced stage non-Hodgkin\u2019s lymphomas with a polymerase chain reaction amplifiable breakpoint of bcl-2 have residual cells containing the bcl-2 rearrangement at evaluation and after treatment. Blood 78, 3275\u20133280 (1991).","journal-title":"Blood"},{"key":"213_CR33","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","volume":"17","author":"BD Cheson","year":"1999","unstructured":"Cheson, B. D. et al. Report of an international workshop to standardize response criteria for non-Hodgkin\u2019s lymphomas. NCI Sponsored International Working Group. J Clin. Oncol. 17, 1244 (1999).","journal-title":"J Clin. Oncol."},{"key":"213_CR34","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","volume":"25","author":"BD Cheson","year":"2007","unstructured":"Cheson, B. D. et al. Revised response criteria for malignant lymphoma. J. Clin. Oncol. 25, 579\u2013586 (2007).","journal-title":"J. Clin. Oncol."},{"key":"213_CR35","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson, B. D. et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J. Clin. Oncol. 32, 3059\u20133068 (2014).","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"213_CR36","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1200\/JCO.2016.70.8651","volume":"35","author":"Qian Shi","year":"2017","unstructured":"Shi, Q. et al. Thirty-month complete response as a surrogate end point in first-line follicular lymphoma therapy: an individual patient-level analysis of multiple randomized trials. J. Clin. Oncol. 35, 552\u2013560 (2016).","journal-title":"Journal of Clinical Oncology"},{"key":"213_CR37","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1016\/S1470-2045(15)00169-2","volume":"16","author":"A Pastore","year":"2015","unstructured":"Pastore, A. et al. Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry. Lancet Oncol. 16, 1111\u20131122 (2015).","journal-title":"Lancet Oncol."},{"key":"213_CR38","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1111\/bjh.14201","volume":"175","author":"YN Blaker","year":"2016","unstructured":"Blaker, Y. N. et al. The tumour microenvironment influences survival and time to transformation in follicular lymphoma in the rituximab era. Br. J. Haematol. 175, 102\u2013114 (2016).","journal-title":"Br. J. Haematol."},{"key":"213_CR39","doi-asserted-by":"publisher","first-page":"2488","DOI":"10.1172\/JCI119433","volume":"99","author":"HP Brezinschek","year":"1997","unstructured":"Brezinschek, H. P. et al. Analysis of the human VH gene repertoire. Differential effects of selection and somatic hypermutation on human peripheral CD5(+)\/IgM+and CD5(-)\/IgM+B cells. J. Clin. Invest. 99, 2488\u20132501 (1997).","journal-title":"J. Clin. Invest."},{"key":"213_CR40","doi-asserted-by":"publisher","first-page":"3088","DOI":"10.1182\/blood-2011-03-343434","volume":"118","author":"A Hadzidimitriou","year":"2011","unstructured":"Hadzidimitriou, A. et al. Is there a role for antigen selection in mantle cell lymphoma? Immunogenetic support from a series of 807 cases. Blood 118, 3088\u20133095 (2011).","journal-title":"Blood"},{"key":"213_CR41","doi-asserted-by":"publisher","first-page":"4467","DOI":"10.1182\/blood-2011-11-393694","volume":"119","author":"A Agathangelidis","year":"2012","unstructured":"Agathangelidis, A. et al. Stereotyped B-cell receptors in one-third of chronic lymphocytic leukemia: a molecular classification with implications for targeted therapies. Blood 119, 4467\u20134475 (2012).","journal-title":"Blood"},{"key":"213_CR42","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.3324\/haematol.2010.025437","volume":"95","author":"S Zibellini","year":"2010","unstructured":"Zibellini, S. et al. Stereotyped patterns of B-cell receptor in splenic marginal zone lymphoma. Haematologica 95, 1792\u20131796 (2010).","journal-title":"Haematologica"},{"key":"213_CR43","doi-asserted-by":"publisher","first-page":"4844","DOI":"10.1182\/blood-2010-11-316737","volume":"117","author":"E Arons","year":"2011","unstructured":"Arons, E. et al. Evidence of canonical somatic hypermutation in hairy cell leukemia. Blood 117, 4844\u20134851 (2011).","journal-title":"Blood"},{"key":"213_CR44","doi-asserted-by":"publisher","first-page":"3112","DOI":"10.1182\/blood-2007-02-069625","volume":"110","author":"D Gonzalez","year":"2007","unstructured":"Gonzalez, D. et al. Immunoglobulin gene rearrangements and the pathogenesis of multiple myeloma. Blood 110, 3112\u20133121 (2007).","journal-title":"Blood"},{"key":"213_CR45","doi-asserted-by":"crossref","first-page":"3072","DOI":"10.1182\/blood.V86.8.3072.3072","volume":"86","author":"FJ Hsu","year":"1995","unstructured":"Hsu, F. J. & Levy, R. Preferential use of the VH4 Ig gene family by diffuse large-cell lymphoma. Blood 86, 3072\u20133082 (1995).","journal-title":"Blood"},{"key":"213_CR46","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1136\/jcp.2006.038984","volume":"60","author":"MA Catherwood","year":"2007","unstructured":"Catherwood, M. A. et al. Improved clonality assessment in germinal centre\/post-germinal centre non-Hodgkin\u2019s lymphomas with high rates of somatic hypermutation. J. Clin. Pathol. 60, 524\u2013528 (2007).","journal-title":"J. Clin. Pathol."},{"key":"213_CR47","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1111\/j.1600-0609.1999.tb01732.x","volume":"62","author":"R Rosenquist","year":"1999","unstructured":"Rosenquist, R., Lindstrom, A., Holmberg, D. & Lindh, J. & Roass G. V. gene family utilization in different B-cell lymphoma subgroups. Eur. J. Haematol. 62, 123\u2013128 (1999).","journal-title":"Eur. J. Haematol."},{"key":"213_CR48","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.1182\/blood-2004-07-2606","volume":"105","author":"P Ghia","year":"2005","unstructured":"Ghia, P. et al. Geographic patterns and pathogenetic implications of IGHV gene usage in chronic lymphocytic leukemia: the lesson of the IGHV3-21 gene. Blood 105, 1678\u20131685 (2005).","journal-title":"Blood"},{"key":"213_CR49","doi-asserted-by":"publisher","first-page":"10209","DOI":"10.1073\/pnas.180316097","volume":"97","author":"IS Lossos","year":"2000","unstructured":"Lossos, I. S. et al. Ongoing immunoglobulin somatic mutation in germinal center B cell-like but not in activated B cell-like diffuse large cell lymphomas. Proc. Natl Acad. Sci. USA 97, 10209\u201310213 (2000).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"213_CR50","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1038\/leu.2010.302","volume":"25","author":"P Ruminy","year":"2011","unstructured":"Ruminy, P. et al. The isotype of the BCR as a surrogate for the GCB and ABC molecular subtypes in diffuse large B-cell lymphoma. Leukemia 25, 681\u2013688 (2011).","journal-title":"Leukemia"},{"key":"213_CR51","doi-asserted-by":"crossref","unstructured":"Medina, A. et al. VDJH gene repertoire analysis in multiple myeloma (MM) patients: correlation with clinical data. Blood 132, 4446 (2018).","DOI":"10.1182\/blood-2018-99-114627"},{"key":"213_CR52","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1046\/j.1365-2141.1997.8492477.x","volume":"96","author":"K Stamatopoulos","year":"1997","unstructured":"Stamatopoulos, K. et al. Follicular lymphoma immunoglobulin kappa light chains are affected by the antigen selection process, but to a lesser degree than their partner heavy chains. Br J. Haematol. 96, 132\u2013146 (1997).","journal-title":"Br J. Haematol."},{"key":"213_CR53","doi-asserted-by":"publisher","first-page":"e359","DOI":"10.1016\/S2352-3026(18)30090-5","volume":"5","author":"M Federico","year":"2018","unstructured":"Federico, M. et al. Rituximab and the risk of transformation of follicular lymphoma: a retrospective pooled analysis. Lancet Haematol. 5, e359\u2013e367 (2018).","journal-title":"Lancet Haematol."},{"key":"213_CR54","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1111\/j.1365-2141.2008.07166.x","volume":"142","author":"D Rossi","year":"2008","unstructured":"Rossi, D. et al. Biological and clinical risk factors of chronic lymphocytic leukaemia transformation to Richter syndrome. Br. J. Haematol. 142, 202\u2013215 (2008).","journal-title":"Br. J. Haematol."}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-019-0213-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-019-0213-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-019-0213-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T16:12:59Z","timestamp":1671207179000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-019-0213-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,17]]},"references-count":54,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2019,7]]}},"alternative-id":["213"],"URL":"https:\/\/doi.org\/10.1038\/s41408-019-0213-9","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,17]]},"assertion":[{"value":"26 November 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors reports grants PI15\/01393, PI18-00410, CAS102P17, GRS 1180\/A\/15, GLD17\/00334, CIBERONC-CB16\/12\/00233 during the conduct of the study, and from Gilead Sciences (GLD15\/00348, GLD16\/00162), Incyte, Janssen, and Amgen outside the submitted work. M.G.A., I.P.C., C.J., V.G.C. and M.E.S. are or were supported by the Spanish government (ISCIII and\/or FEHH). Consulting fees and\/or non-financial support were reported from Abbvie (M.G.), Amgen (N.P., M.D.C), BMS (R.G-S., M.D.C.), Celgene (N.P., A.M., M.D.C), Gilead (A.M., M.G., M.D.C.), Incyte (R.G-S.), Janssen (N.P., A.M., R.G-S., M.G., M.D.C., M.A.), Kite (M.D.C.), MSD (M.D.C.), Novartis (S.A-A., M.D.C.), Prothena (V.G-C.), Roche (A.M., M.G., M.D.C.), Servier (A.M.), Takeda (N.P., R.G-S., M.D.C.), and Weber (N.P.). R.G-S. is the president of the Spanish Society of Haematology. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"52"}}